Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Unicycive Therapeutics Inc (UNCY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Unicycive Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.970 -0.070    -6.73%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
0.970
-0.000
-0.000%
18:30:59 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 498,047
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.933 - 1.050
Unicycive Therapeutics 0.970 -0.070 -6.73%

Unicycive Therapeutics Inc Company Profile

 
Get an in-depth profile of Unicycive Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee’s Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Contact Information

Address 4300 El Camino Real Suite 210
Los Altos, 94022
United States
Phone 650 351 4495
Fax -

Top Executives

Name Age Since Title
Myles Selig Wolf 51 - Member of Scientific Advisory Board
Sandeep Laumas 54 2018 Independent Director
Glenn Matthew Chertow - - Member of Scientific Advisory Board
John L. Ryan 80 2018 Independent Director
Pablo E. Pergola - - Member of Scientific Advisory Board
Ravindra L. Mehta - - Member of Scientific Advisory Board
Sara Kenkare-Mitra 55 2023 Director
Shalabh K. Gupta 50 2016 Founder, Chairman, CEO & President
Gaurav Aggarwal 50 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

UNCY Comments

Write your thoughts about Unicycive Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Joe Ramella
Joe Ramella Feb 06, 2024 11:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lets Go!!!
László Rádi
László Rádi Mar 27, 2023 4:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
next scam
Joe Ramella
Joe Ramella Aug 16, 2021 12:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So https://investing.com shows the neagative earnings news but not the positive coverage by Roth and price target of $13.50? I see whats going on here!
Joe Ramella
Joe Ramella Aug 09, 2021 10:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Coverage initiaded by Roth Capital with $13.50 price tagert!!
Raul AlKhuwaitem
Raul AlKhuwaitem Jun 15, 2021 5:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
When we can buy it?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email